Driving assessment in preclinical Alzheimer's disease: progress to date and the path forward
- PMID: 36348410
- PMCID: PMC9641948
- DOI: 10.1186/s13195-022-01109-1
Driving assessment in preclinical Alzheimer's disease: progress to date and the path forward
Abstract
Background: Changes in driving behaviour may start at the preclinical stage of Alzheimer's disease (AD), where the underlying AD biological process has begun in the presence of cognitive normality. Here, we summarize the emerging evidence suggesting that preclinical AD may impact everyday driving behaviour. MAIN: Increasing evidence links driving performance and behaviour with AD biomarkers in cognitively intact older adults. These studies have found subtle yet detectable differences in driving associated with AD biomarker status among cognitively intact older adults.
Conclusion: Recent studies suggest that changes in driving, a highly complex activity, are linked to, and can indicate the presence of, neuropathological AD. Future research must now examine the internal and external validity of driving for widespread use in identifying biological AD.
Keywords: Alzheimer’s disease; Automobile driving; Biomarker; GPS; Mobile technology; Naturalistic; Preclinical.
© 2022. The Author(s).
Conflict of interest statement
The authors declare that they have no competing interests.
Figures
Similar articles
-
A 2.5-Year Longitudinal Assessment of Naturalistic Driving in Preclinical Alzheimer's Disease.J Alzheimers Dis. 2019;68(4):1625-1633. doi: 10.3233/JAD-181242. J Alzheimers Dis. 2019. PMID: 30958365 Free PMC article.
-
GPS driving: a digital biomarker for preclinical Alzheimer disease.Alzheimers Res Ther. 2021 Jun 14;13(1):115. doi: 10.1186/s13195-021-00852-1. Alzheimers Res Ther. 2021. PMID: 34127064 Free PMC article.
-
Adverse driving behaviors are associated with sleep apnea severity and age in cognitively normal older adults at risk for Alzheimer's disease.Sleep. 2022 Jun 13;45(6):zsac070. doi: 10.1093/sleep/zsac070. Sleep. 2022. PMID: 35303111 Free PMC article.
-
Prevalence and risk of progression of preclinical Alzheimer's disease stages: a systematic review and meta-analysis.Alzheimers Res Ther. 2019 Jan 15;11(1):7. doi: 10.1186/s13195-018-0459-7. Alzheimers Res Ther. 2019. PMID: 30646955 Free PMC article.
-
Detectable Neuropsychological Differences in Early Preclinical Alzheimer's Disease: A Meta-Analysis.Neuropsychol Rev. 2017 Dec;27(4):305-325. doi: 10.1007/s11065-017-9345-5. Epub 2017 May 11. Neuropsychol Rev. 2017. PMID: 28497179 Free PMC article. Review.
Cited by
-
Decoding Alzheimer's Disease With Depression: Molecular Insights and Therapeutic Target.J Cell Mol Med. 2025 Mar;29(5):e70454. doi: 10.1111/jcmm.70454. J Cell Mol Med. 2025. PMID: 40074694 Free PMC article.
-
Assessing and projecting the global impacts of Alzheimer's disease.Front Public Health. 2025 Jan 15;12:1453489. doi: 10.3389/fpubh.2024.1453489. eCollection 2024. Front Public Health. 2025. PMID: 39882109 Free PMC article.
-
The Influence of Personality Traits on Driving Behaviors in Preclinical Alzheimer Disease.Alzheimer Dis Assoc Disord. 2024 Jul-Sep 01;38(3):241-248. doi: 10.1097/WAD.0000000000000632. Epub 2024 Aug 23. Alzheimer Dis Assoc Disord. 2024. PMID: 39177169
References
-
- Rosenbloom S. Sustainability and automobility among the elderly: an international assessment. Transportation. 2001;28:375–408. doi: 10.1023/A:1011802707259. - DOI
-
- Spinney JEL, Newbold KB, Scott DM, Vrkljan B, Grenier A. The impact of driving status on out-of-home and social activity engagement among older Canadians. J Transp Geogr. 2020;85:102698. doi: 10.1016/j.jtrangeo.2020.102698. - DOI
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical